Trials / Unknown
UnknownNCT05268913
Towards Early Detection of Breast Cancer in High Risk Population
Robust EArly Detection of bReast Cancer in hIgh riSK Premenopausal Population Using Novel Lipid Based Imaging Methods
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 120 (estimated)
- Sponsor
- University of Aberdeen · Academic / Other
- Sex
- Female
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
Breast cancer is a major and growing health challenge, and the leading cause of cancer in women. As population obesity rates increase, the number of new breast cancer diagnosis continues to rise. Despite treatment advances, breast cancer remains an important cause of premature mortality, taking women in the prime of life. Although underlying susceptibility caused by mutation in the genes including BRCA1/2 is increasingly identified, current pre-symptomatic screening for the general population and those at high genetic risk remains sub-optimal, with high false negative and positive rates. Alteration of breast lipid composition has been observed by us and others in patients with breast cancer and is thought to precede onset. We have developed and tested a novel method to allow a standard 3T MRI scanner to perform quantitative 3D mapping of specific lipid molecules in the breast. We will investigate if this method can detect very early breast cancers, and compare the amount and spread of lipid composition in breast tissue of premenopausal women with very high genetic risk of breast cancer, women with breast cancer and women with obesity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | MRI scan | Participants will undertake a magnetic resonance imaging scan. |
| BIOLOGICAL | Blood test | Participants will undertake a fasting blood test. |
Timeline
- Start date
- 2022-03-01
- Primary completion
- 2024-05-01
- Completion
- 2024-05-01
- First posted
- 2022-03-07
- Last updated
- 2022-03-07
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT05268913. Inclusion in this directory is not an endorsement.